Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of dienogest treatment in patients who had received dienogest for 12 months or more to treat endometriosis. METHODS: We analyzed the clinical data of 188 women with endometriosis who had been treated with 2 mg of dienogest once a day for 12 months or more at a single institute. We evaluated changes in endometriosis-associated pain and endometrioma size, recurrence rate, and adverse events following dienogest administration. Bone mineral density (BMD) was measured in patients who were prescribed dienogest for more than 18 months. RESULTS: Pain was significantly reduced at 12 months after dienogest medication. In those treated with dienogest due to recurrent endometrioma, the size of the endometrioma was significantly decreased at the 12-month and 18-month follow-ups. We found only one case of sonographic recurrence during dienogest administration among those who were treated postoperatively to prevent recurrence (1 of 114, 0.9%). The most common adverse drug reaction was uterine bleeding (3.2%), and other adverse events were generally tolerable and associated with low discontinuation rates (5.2%). Among the 50 patients in whom BMD was measured, 10 patients (20%) had a Z-score below the expected range for age. CONCLUSION: The administration of dienogest for a year or more seems to be highly effective in preventing recurrence after surgery, reducing endometriosis-associated pain, and decreasing the size of recurrent endometrioma, with a favorable safety and tolerability profile. However, BMD should be checked in patients on long-term medication due to possible bone loss in some women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 4×
“216 showed that dienogest was as effective as leuprolide acetate (LA), which is considered to be one of the current standard therapies for endometriosis, in relieving the pain associated with endometriosis [7].”
BackgroundInfluentialStrowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 4×
“enogest for 12 weeks was more effective than placebo in reducing endometriosis-associated pain with tolerable adverse events [6].”
BackgroundInfluentialReduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1941-7 · Cited by 200
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
Foster, R. H., & Wilde, M. I. (1998) · Drugs · doi:10.2165/00003495-199856050-00007 · Cited by 87
Cited by
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa009 · Cited by 166
Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery?
Del Forno, S., Mabrouk, M., Arena, A., Mattioli, G., Giaquinto, I., Paradisi, R., & Seracchioli, R. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.04.010 · Cited by 88
Zakhari, A., Edwards, D., Ryu, M., Matelski, J. J., Bougie, O., & Murji, A. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2020.05.007 · Cited by 86
Römer, T. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4864-8 · Cited by 82
Effect of Dienogest therapy on the size of the endometrioma
Vignali, M., Belloni, G. M., Pietropaolo, G., Barbasetti Di Prun, A., Barbera, V., Angioni, S., & Pino, I. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1725965 · Cited by 50
Metadata
- Authors
- Park, S. Y., Kim, S. H., Chae, H. D., Kim, C.-H., & Kang, B. M.
- Venue
- Clinical and Experimental Reproductive Medicine
- Published
- 2016
- Volume
- 43
- Issue
- 4
- Pages
- 215
- ISSN
- 2093-8896 (ISSN-L)
- 2233-8233
- 2233-8241
- OpenAlex
- W2571030170
- Cited by
- 71
- References
- 8
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.